Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD

NCT ID: NCT01025739

Last Updated: 2015-04-29

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: PHASE2
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-01-31
• Study Completion Date: 2011-02-28

Brief Summary

Objectives of the Study:

The primary objective of this study is to evaluate the relative merits, safety and effectiveness of the tailored TIF2 procedure in treating GERD patients who have persistent GERD symptoms despite PPI therapy.

The secondary objective of the study is to evaluate the effectiveness of the tailored TIF procedure in restoring the antireflux barrier and eliminating GE reflux.

Type of Study:

Prospective, non-randomized, uncontrolled Study Duration 12 months Number of Patients 20

Inclusion Criteria:

Age 18-70 years, on daily PPIs for > 6 months, persistent GERD symptoms despite PPI therapy, anatomic disruption of the gastroesophageal valve to a Hill Grade II-III, evidence of one of the following while on PPI therapy: (1) erosive esophagitis (erosions or ulcerations during endoscopy); (2) abnormal ambulatory pH study; or (3) biopsy confirmed changes characteristic of reflux esophagitis; acceptable esophageal motility (by either manometry or video esophagogram), hiatal hernia no larger than 2 cm, patient willing to cooperate with post-operative dietary recommendations and assessment tests, signed informed consent

Exclusion Criteria:

BMI > 40, hiatal hernia > 2 cm, esophagitis grade D, esophageal ulcer, fixed esophageal stricture, gastric motility disorders, previous splenectomy, pregnancy (female), immunosuppression, ASA > 2, portal hypertension and/or varices, history of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis, active gastro-duodenal ulcer disease, gastric outlet obstruction or stenosis, gastroparesis or delayed gastric emptying, coagulation disorders

Interventions:

Treatment: Tailored transoral incisionless fundoplication (TIF2) using EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA)

Evaluation Criteria:

Primary Outcome Measure 24 hour pH impedance study: change in Johnson DeMeester scores; GERD-HRQOL scores Secondary Outcome Measures PPI usage, GERD symptoms at 6 and 12 months vs. baseline off PPI's, total number of reflux episodes, and Symptom Association Probability while off PPI.

Safety: Adverse events will be mapped to standard terms and reported.

Conditions

Gastroesophageal Reflux Disease (GERD)

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Interventions

EsophyX™ system with SerosaFuse fasteners

The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age 18-70 years
• On daily PPIs for > 6 months
• Persistent GERD symptoms despite PPI therapy
• Anatomic disruption of the gastroesophageal valve to a Hill Grade II-III
• Evidence of one of the following while on PPI therapy:

• Erosive esophagitis (erosions or ulcerations during endoscopy)
• Abnormal ambulatory pH study
• Biopsy confirmed changes characteristic of reflux esophagitis
• Acceptable esophageal motility (by either manometry or video esophagogram)
• Hiatal hernia no larger than 2 cm
• Patient willing to cooperate with post-operative dietary recommendations and assessment tests
• Signed informed consent

Exclusion Criteria

• BMI > 40
• Hiatal hernia > 2 cm
• Esophagitis grade D
• Esophageal ulcer
• Esophageal stricture
• Esophageal motility disorder
• Prior splenectomy
• Pregnancy or plans for pregnancy in the next 12 months (in females)
• Immunosuppression
• ASA > 2
• Portal hypertension and/or varices
• History of previous resective gastric or esophageal surgery, cervical spine fusion, Zenker's diverticulum, esophageal epiphrenic diverticulum, achalasia, scleroderma or dermatomyositis, eosinophilic esophagitis, or cirrhosis
• Active gastro-duodenal ulcer disease
• Gastric outlet obstruction or stenosis
• Gastroparesis or delayed gastric emptying confirmed by solid-phase gastric emptying study if patient complains of postprandial satiety during assessment
• Coagulation disorders

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AHS Cancer Control Alberta

OTHER

Sponsor Role: collaborator

University of Alberta

OTHER

Sponsor Role: lead

Responsible Party

Daniel Birch

MSc, MD, FRCSC, FACS

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

CAMIS, Royal Alexandra Hospital

Edmonton, Alberta, Canada

Countries

Canada

References

El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26. doi: 10.1016/j.cgh.2006.09.016. Epub 2006 Dec 4.

Reference Type: BACKGROUND

PMID: 17142109 (View on PubMed)

Lundell L. Surgery of gastroesophageal reflux disease: a competitive or complementary procedure? Dig Dis. 2004;22(2):161-70. doi: 10.1159/000080315.

Reference Type: BACKGROUND

PMID: 15383757 (View on PubMed)

Metz DC. Managing gastroesophageal reflux disease for the lifetime of the patient: evaluating the long-term options. Am J Med. 2004 Sep 6;117 Suppl 5A:49S-55S. doi: 10.1016/j.amjmed.2004.07.009.

Reference Type: BACKGROUND

PMID: 15478853 (View on PubMed)

Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006 Jun 24;367(9528):2086-100. doi: 10.1016/S0140-6736(06)68932-0.

Reference Type: BACKGROUND

PMID: 16798392 (View on PubMed)

Nandurkar S, Talley NJ. Epidemiology and natural history of reflux disease. Baillieres Best Pract Res Clin Gastroenterol. 2000 Oct;14(5):743-57. doi: 10.1053/bega.2000.0122.

Reference Type: BACKGROUND

PMID: 11003807 (View on PubMed)

Smout AJ. The patient with GORD and chronically recurrent problems. Best Pract Res Clin Gastroenterol. 2007;21(3):365-78. doi: 10.1016/j.bpg.2007.01.007.

Reference Type: BACKGROUND

PMID: 17544105 (View on PubMed)

Stylopoulos N, Rattner DW. The history of hiatal hernia surgery: from Bowditch to laparoscopy. Ann Surg. 2005 Jan;241(1):185-93. doi: 10.1097/01.sla.0000149430.83220.7f.

Reference Type: BACKGROUND

PMID: 15622007 (View on PubMed)

Jones MP, Sloan SS, Rabine JC, Ebert CC, Huang CF, Kahrilas PJ. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol. 2001 Jun;96(6):1711-7. doi: 10.1111/j.1572-0241.2001.03926.x.

Reference Type: BACKGROUND

PMID: 11419819 (View on PubMed)

Mittal RK. Hiatal hernia: myth or reality? Am J Med. 1997 Nov 24;103(5A):33S-39S. doi: 10.1016/s0002-9343(97)00318-5. No abstract available.

Reference Type: BACKGROUND

PMID: 9422620 (View on PubMed)

Mittal RK. Hiatal hernia and gastroesophageal reflux: another attempt to resolve the controversy. Gastroenterology. 1993 Sep;105(3):941-3. doi: 10.1016/0016-5085(93)90917-2. No abstract available.

Reference Type: BACKGROUND

PMID: 8359662 (View on PubMed)

Moss SF, Kidd M, Modlin IM. The status of the hiatus: the role of hernia in gastroesophageal reflux disease. J Clin Gastroenterol 2007;41:S144-S153

Reference Type: BACKGROUND

Rydberg L, Ruth M, Lundell L. Mechanism of action of antireflux procedures. Br J Surg. 1999 Mar;86(3):405-10. doi: 10.1046/j.1365-2168.1999.01025.x.

Reference Type: BACKGROUND

PMID: 10201789 (View on PubMed)

Ahroni JH, Montgomery KF, Watkins BM. Laparoscopic adjustable gastric banding: weight loss, co-morbidities, medication usage and quality of life at one year. Obes Surg. 2005 May;15(5):641-7. doi: 10.1381/0960892053923716.

Reference Type: BACKGROUND

PMID: 15946454 (View on PubMed)

Cadiere GB, Rajan A, Rqibate M, Germay O, Dapri G, Himpens J, Gawlicka AK. Endoluminal fundoplication (ELF)--evolution of EsophyX, a new surgical device for transoral surgery. Minim Invasive Ther Allied Technol. 2006;15(6):348-55. doi: 10.1080/13645700601040024.

Reference Type: BACKGROUND

PMID: 17190659 (View on PubMed)

Jobe BA, O'Rourke RW, McMahon BP, Gravesen F, Lorenzo C, Hunter JG, Bronner M, Kraemer SJ. Transoral endoscopic fundoplication in the treatment of gastroesophageal reflux disease: the anatomic and physiologic basis for reconstruction of the esophagogastric junction using a novel device. Ann Surg. 2008 Jul;248(1):69-76. doi: 10.1097/SLA.0b013e31817c9630.

Reference Type: BACKGROUND

PMID: 18580209 (View on PubMed)

Cadiere GB, Rajan A, Germay O, Himpens J. Endoluminal fundoplication by a transoral device for the treatment of GERD: A feasibility study. Surg Endosc. 2008 Feb;22(2):333-42. doi: 10.1007/s00464-007-9618-9. Epub 2007 Dec 11.

Reference Type: BACKGROUND

PMID: 18071818 (View on PubMed)

Cadiere GB, Buset M, Muls V, Rajan A, Rosch T, Eckardt AJ, Weerts J, Bastens B, Costamagna G, Marchese M, Louis H, Mana F, Sermon F, Gawlicka AK, Daniel MA, Deviere J. Antireflux transoral incisionless fundoplication using EsophyX: 12-month results of a prospective multicenter study. World J Surg. 2008 Aug;32(8):1676-88. doi: 10.1007/s00268-008-9594-9.

Reference Type: BACKGROUND

PMID: 18443855 (View on PubMed)

Huber-Lang M, Henne-Bruns D, Schmitz B, Wuerl P. Esophageal perforation: principles of diagnosis and surgical management. Surg Today. 2006;36(4):332-40. doi: 10.1007/s00595-005-3158-5.

Reference Type: BACKGROUND

PMID: 16554990 (View on PubMed)

Bouvy ND, Witteman BPL, Jobe BA, Lorenzo C, Kraemer SJM, Gawlicka AK, McMahon B, Gravesen FH, Masclee A, Hameeteman W, Koek GH, Perry K. Tailored reconstruction of the esophagogastric junction using transoral incisionless fundoplication: a feasibility study. Surg Endosc 2008

Reference Type: BACKGROUND

Witteman BP, Strijkers R, de Vries E, Toemen L, Conchillo JM, Hameeteman W, Dagnelie PC, Koek GH, Bouvy ND. Transoral incisionless fundoplication for treatment of gastroesophageal reflux disease in clinical practice. Surg Endosc. 2012 Nov;26(11):3307-15. doi: 10.1007/s00464-012-2324-2. Epub 2012 May 31.

Reference Type: BACKGROUND

PMID: 22648098 (View on PubMed)

Bouvy ND, Witteman BPL, de Vries E, van Dam R, Greve JW, Gawlicka AK, Masclee A, Hameeteman W, Koek GH. EsophyX transoral incisionless fundoplication for the treatment of GERD in clinical practice. Gastrointest Endosc 2008

Reference Type: BACKGROUND

Lundell LR, Dent J, Bennett JR, Blum AL, Armstrong D, Galmiche JP, Johnson F, Hongo M, Richter JE, Spechler SJ, Tytgat GN, Wallin L. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999 Aug;45(2):172-80. doi: 10.1136/gut.45.2.172.

Reference Type: BACKGROUND

PMID: 10403727 (View on PubMed)

Jobe BA, Kahrilas PJ, Vernon AH, Sandone C, Gopal DV, Swanstrom LL, Aye RW, Hill LD, Hunter JG. Endoscopic appraisal of the gastroesophageal valve after antireflux surgery. Am J Gastroenterol. 2004 Feb;99(2):233-43. doi: 10.1111/j.1572-0241.2004.04042.x.

Reference Type: BACKGROUND

PMID: 15046210 (View on PubMed)

Hill LD, Kozarek RA, Kraemer SJ, Aye RW, Mercer CD, Low DE, Pope CE 2nd. The gastroesophageal flap valve: in vitro and in vivo observations. Gastrointest Endosc. 1996 Nov;44(5):541-7. doi: 10.1016/s0016-5107(96)70006-8.

Reference Type: BACKGROUND

PMID: 8934159 (View on PubMed)

Other Identifiers

Pro00004475

Identifier Type: -

Identifier Source: org_study_id